Daniel Halperin, MD

Medical Oncology, University of Texas MD Anderson Cancer Center

Board of Directors, Research Committee

Dr. Halperin is a medical oncologist and clinical investigator focused on the development of novel treatments for patients with neuroendocrine tumors (NETs), in addition to providing high-quality clinical care to patients with NETs and other gastrointestinal cancers. He leads clinical trials of new drugs for patients with NETs at MD Anderson and works together with a team of laboratory and population scientists to understand more fully the molecular underpinnings and clinical manifestations of neuroendocrine tumors. He is also a member of the Neuroendocrine and Adrenal Tumor guideline committee of the National Comprehensive Cancer Network, contributing to evidence-based guidelines for the care of NET patients. Dr. Halperin has a particular interest in the immunology of neuroendocrine tumors and the use of immunotherapy for patients with NETs. As such, he has received peer-reviewed funding from the Neuroendocrine Tumor Research Foundation, as well as a Career Development Award from the American Society of Clinical Oncology, to understand the immunology of NETs and leads a clinical trial of immunotherapy with atezolizumab and bevacizumab for patients with specific rare solid tumors, including two separate cohorts of patients with advanced well-differentiated NETs.

Ongoing clinical trials include:
1. A Phase II, Single-Arm Open-Label Study of the Combination Of Atezolizumab and Bevacizumab in Rare Solid Tumors (NCT03074513).

2. An open-label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal or thoracic origin who have progressed on prior therapy. (NCT02955069)

3. PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (NCT02936323).

4. Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02101918) - closed to new patient enrollment.

More about Dr. Halperin